Targeting tumor exosome PD-L1 to improve cancer immunotherapy
Targeting exosomal PDL1 to improve immunotherapy
This project tests whether blocking PD-L1 carried on tiny particles shed by tumors can help people with melanoma respond better to anti–PD-1 immunotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11187259 on NIH RePORTER |
What this research studies
If you have metastatic melanoma and are getting or may get anti–PD-1 drugs, this work looks at PD-L1 carried on tumor-derived exosomes in your blood and how that affects immune T cells. The team measures exosomal PD-L1 levels in patient plasma over time as a possible early signal of whether the treatment will work. They are developing a quantitative blood test and exploring ways to neutralize exosomal PD-L1 so CD8+ T cells can fight the tumor more effectively. The goal is to give doctors earlier information to personalize treatment and avoid unnecessary toxic combinations.
Who could benefit from this research
Good fit: Ideal candidates are people with metastatic melanoma who are starting or already receiving anti–PD-1 immunotherapy and can provide blood samples.
Not a fit: People without PD-1–treated cancers, those with cancer types not linked to exosomal PD-L1, or patients not eligible for immunotherapy are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this could allow doctors to predict who will benefit from anti–PD-1 drugs and improve responses while reducing exposure to toxic combination therapies.
How similar studies have performed: Prior research, including a 2018 Nature report, linked circulating exosomal PD-L1 levels to response to anti–PD-1 therapy, but using it as a routine clinical test or therapeutic target is still new.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Guo, Wei — Wistar Institute
- Study coordinator: Guo, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.